Yeah, we’re very excited that we have one more option for treating our patients with PV. Rusfertide is a great scientific advancement in which we utilize the ability of modulating a hepcidin pathway to avoid phlebotomy. This is a very specific therapy that is very capable of delivering the success as we define on those studies, which is eliminating phlebotomy. So rusfertide is not a cytoreductive therapy...
Yeah, we’re very excited that we have one more option for treating our patients with PV. Rusfertide is a great scientific advancement in which we utilize the ability of modulating a hepcidin pathway to avoid phlebotomy. This is a very specific therapy that is very capable of delivering the success as we define on those studies, which is eliminating phlebotomy. So rusfertide is not a cytoreductive therapy. rusfertide is not going to replace our standard platform of how we treat patients with PV, especially the high-risk patients. So for high-risk patients, cytoreductive therapy with interferon or as a preferred agent or others, like hydroxyurea, remains the platform of how we treat patients. Rusfertide would be useful in these patients who are still in cytoreductive therapy and still require phlebotomy. So a combination of interferon and rusfertide is very plausible, actually, in many patients in the future. Now, the question comes to patients who are lower risk, in which cytoreductive therapy is not yet absolutely necessary or indicated, and those patients are being managed by phlebotomy only, those patients are absolutely on label for rusfertide therapy. On the same token, and this is a topic of interest for me personally with an upcoming clinical trial, is that interferons also have shown a very promising activity in patients with low-risk PV in terms of disease modification, clinical responses, and molecular responses. Now, this was studied in a limited prospective European study, but we are in the process of designing a global interventional clinical trial for low-risk PV patients that will be randomized, in which patients who are low-risk PV patients will be randomized to early intervention with interferon. Now, when that work is complete, that will inform our future care for patients with low-risk PV and define the role of interferons in low-risk PV. That being said, rusfertide remains a very important tool for hematocritic control and avoidance of phlebotomy in parallel to whatever else we’re doing, both in high-risk PV patients and in low-risk PV patients. And it’s definitely a tool that’s here to stay. We already have second and third generation agents in the works, so obviously there’s a significant buy-in from the community that this is an important tool for our future patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.